Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (opens original article in a new tab)

Definium Therapeutics reported positive Phase 3 trial results for DT120 ODT, an orally disintegrating tablet for major depressive disorder, showing significant improvement in patient outcomes.

• Definium Therapeutics announced positive topline results from Phase 3 Emerge study of DT120 ODT in MDD.
• DT120 ODT showed statistically significant improvement in MADRS scores compared to placebo at week 6, 12, and week 1.
• DT120 ODT was generally well tolerated with no new safety signals identified.